title: Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis.
abstract: OBJECTIVE
  To analyze the effects of aminobisphosphonates and thiazides on renal lithogenic activity and bone mineral density in patients with recurring renal calcium lithiasis.
  
  
  METHODS
  A prospective cohort study with 3 years of clinical follow-up data was performed. The study included 2 groups of patients with recurring calcium lithiasis, hypercalciuria, and bone mineral density loss. Group 1 included 35 patients who underwent treatment with 70 mg/wk alendronate. Group 2 included 35 patients who underwent treatment with 50 mg/d hydrochlothiazide and 70 mg/wk alendronate. Biochemical analysis was performed at baseline, 6 months, and 2 years, bone densitometry at baseline and 2 years, and clinical follow-up during the 3 years of treatment. The biochemical variables from the blood and urine samples, recurrent lithiasis, and bone mineral density were analyzed.
  
  
  RESULTS
  Age, sex, baseline biochemical markers, and bone density showed no differences between the 2 treatment groups at the onset of treatment. After 2 years of treatment, group 1 showed a significant decrease in bone turnover markers and calciuria and significant improvement in bone mineral density. After 2 years of treatment, group 2 showed a decrease in calciuria and bone markers. At 2 years, the decrease in calciuria and the improvement in bone mineral density were greater in group 2 than in group 1, and the difference was statistically significant.
  
  
  CONCLUSIONS
  Aminobisphosphonates improve bone mineral density and slow lithogenic activity; however, administration of aminobisphosphonates in association with thiazides produced the same clinical effects and also reduced calciuria and improved bone mineral density.
authors: Department of Urology, San Cecilio University Hospital, Granada, Spain. arrabalp@ono.com
authors: Miguel Angel
authors: MA
authors: Arrabal-Polo
authors: Salvador
authors: S
authors: Arias-Santiago
authors: Tomas
authors: T
authors: de Haro-Muñoz
authors: Adriana
authors: A
authors: Lopez-Ruiz
authors: Jacinto
authors: J
authors: Orgaz-Molina
authors: Samuel
authors: S
authors: Gonzalez-Torres
authors: Armando
authors: A
authors: Zuluaga-Gomez
authors: Miguel
authors: M
authors: Arrabal-Martin
mesh_terms: D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D002118:Calcium / Q000032:analysis; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D053565:Hypercalciuria / Q000188:drug therapy*; D007669:Kidney Calculi / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D053040:Nephrolithiasis / Q000188:drug therapy*; D010024:Osteoporosis / Q000188:drug therapy; D011446:Prospective Studies; D012008:Recurrence; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; D002118:Calcium; D019386:Alendronate